Cargando…
Generation of a Vero-Based Packaging Cell Line to Produce SV40 Gene Delivery Vectors for Use in Clinical Gene Therapy Studies
Replication-defective (RD) recombinant simian virus 40 (SV40)-based gene delivery vectors hold a great potential for clinical applications because of their presumed non-immunogenicity and capacity to induce immune tolerance to the transgene products in humans. However, the clinical use of SV40 vecto...
Autores principales: | Toscano, Miguel G., van der Velden, Jeroen, van der Werf, Sybrand, Odijk, Machteld, Roque, Ana, Camacho-Garcia, Rafael J., Herrera-Gomez, Irene G., Mancini, Irene, de Haan, Peter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5537168/ https://www.ncbi.nlm.nih.gov/pubmed/28791314 http://dx.doi.org/10.1016/j.omtm.2017.06.007 |
Ejemplares similares
-
Cre Recombinase Mediates the Removal of Bacterial Backbone to Efficiently Generate rSV40
por: Shi, Xiaoxia, et al.
Publicado: (2018) -
Simian virus 40 (SV40)-transgenic mice that develop tumors are specifically tolerant to SV40 T antigen
Publicado: (1987) -
SV40 and human mesothelioma
por: Carbone, Michele, et al.
Publicado: (2020) -
Hepatocarcinogenesis in Transgenic Mice Carrying Albumin‐promoted SV40 T Antigen Gene
por: Hino, Okio, et al.
Publicado: (1991) -
SV40: A Human Pathogen?
por: Garcea, Robert L.
Publicado: (2001)